Conatus Pharmaceuticals (CNAT) Misses Q1 EPS by 1c

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q1 EPS of ($0.36), $0.01 worse than the analyst estimate of ($0.35).

Cash, cash equivalents and marketable securities were $32.6 million at March 31, 2016, compared with $36.5 million at December 31, 2015. The company believes current financial resources are sufficient to maintain operations and ongoing clinical development activities for at least the next 12 months.

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance
• EXL closes $1 billion credit facility, up from $600 million